Taking Lessons from CAR-T Cells and Going Beyond: Tailoring Design and Signaling for CAR-NK Cells in Cancer Therapy
- PMID: 35371071
- PMCID: PMC8971283
- DOI: 10.3389/fimmu.2022.822298
Taking Lessons from CAR-T Cells and Going Beyond: Tailoring Design and Signaling for CAR-NK Cells in Cancer Therapy
Abstract
Cancer immunotherapies utilize the capabilities of the immune system to efficiently target malignant cells. In recent years, chimeric antigen receptor (CAR) equipped T cells showed promising results against B cell lymphomas. Autologous CAR-T cells require patient-specific manufacturing and thus extensive production facilities, resulting in high priced therapies. Along with potentially severe side effects, these are the major drawbacks of CAR-T cells therapies. Natural Killer (NK) cells pose an alternative for CAR equipped immune cells. Since NK cells can be safely transferred from healthy donors to cancer patients, they present a suitable platform for an allogeneic "off-the-shelf" immunotherapy. However, administration of activated NK cells in cancer therapy has until now shown poor anti-cancer responses, especially in solid tumors. Genetic modifications such as CARs promise to enhance recognition of tumor cells, thereby increasing anti-tumor effects and improving clinical efficacy. Although the cell biology of T and NK cells deviates in many aspects, the development of CAR-NK cells frequently follows within the footsteps of CAR-T cells, meaning that T cell technologies are simply adopted to NK cells. In this review, we underline the unique properties of NK cells and their potential in CAR therapies. First, we summarize the characteristics of NK cell biology with a focus on signaling, a fine-tuned interaction of activating and inhibitory receptors. We then discuss why tailored NK cell-specific CAR designs promise superior efficacy compared to designs developed for T cells. We summarize current findings and developments in the CAR-NK landscape: different CAR formats and modifications to optimize signaling, to target a broader pool of antigens or to increase in vivo persistence. Finally, we address challenges beyond NK cell engineering, including expansion and manufacturing, that need to be addressed to pave the way for CAR-NK therapies from the bench to the clinics.
Keywords: CAR-NK cell; CAR-T cells; NK cell receptors and ligands; allogenic cell therapy; cell signaling; chimeric antigen receptor (CAR); gene therapy; immunotherapy.
Copyright © 2022 Ruppel, Fricke, Köhl and Schmiedel.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
Similar articles
-
CAR-NK Cells: From Natural Basis to Design for Kill.Front Immunol. 2021 Dec 14;12:707542. doi: 10.3389/fimmu.2021.707542. eCollection 2021. Front Immunol. 2021. PMID: 34970253 Free PMC article. Review.
-
Chimeric Antigen Receptor-Engineered Natural Killer (CAR NK) Cells in Cancer Treatment; Recent Advances and Future Prospects.Stem Cell Rev Rep. 2021 Dec;17(6):2081-2106. doi: 10.1007/s12015-021-10246-3. Epub 2021 Sep 2. Stem Cell Rev Rep. 2021. PMID: 34472037 Free PMC article. Review.
-
Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy.J Hematol Oncol. 2020 Dec 7;13(1):168. doi: 10.1186/s13045-020-00998-9. J Hematol Oncol. 2020. PMID: 33287875 Free PMC article. Review.
-
Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.Front Immunol. 2020 Aug 7;11:1965. doi: 10.3389/fimmu.2020.01965. eCollection 2020. Front Immunol. 2020. PMID: 32903482 Free PMC article. Review.
-
CAR-NK cells: A promising cellular immunotherapy for cancer.EBioMedicine. 2020 Sep;59:102975. doi: 10.1016/j.ebiom.2020.102975. Epub 2020 Aug 24. EBioMedicine. 2020. PMID: 32853984 Free PMC article. Review.
Cited by
-
Beyond CAR-T: The rise of CAR-NK cell therapy in asthma immunotherapy.J Transl Med. 2024 Aug 5;22(1):736. doi: 10.1186/s12967-024-05534-8. J Transl Med. 2024. PMID: 39103889 Free PMC article. Review.
-
Advances in CAR-NK cell therapy for hematological malignancies.Front Immunol. 2024 Jun 28;15:1414264. doi: 10.3389/fimmu.2024.1414264. eCollection 2024. Front Immunol. 2024. PMID: 39007146 Free PMC article. Review.
-
Development of KoRV-pseudotyped lentiviral vectors for efficient gene transfer into freshly isolated immune cells.Gene Ther. 2024 Jul;31(7-8):378-390. doi: 10.1038/s41434-024-00454-0. Epub 2024 Apr 29. Gene Ther. 2024. PMID: 38684788 Free PMC article.
-
CAR NK Cell Therapy for the Treatment of Metastatic Melanoma: Potential & Prospects.Cells. 2023 Nov 30;12(23):2750. doi: 10.3390/cells12232750. Cells. 2023. PMID: 38067178 Free PMC article. Review.
-
CD44v6 specific CAR-NK cells for targeted immunotherapy of head and neck squamous cell carcinoma.Front Immunol. 2023 Nov 10;14:1290488. doi: 10.3389/fimmu.2023.1290488. eCollection 2023. Front Immunol. 2023. PMID: 38022580 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources